Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 3,080,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Boxer Capital Management, Llc sold 3,080,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $3.14, for a total value of $9,671,200.00. Following the completion of the transaction, the insider now owns 3,610,642 shares in the company, valued at $11,337,415.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Boxer Capital Management, Llc also recently made the following trade(s):

• On Friday, October 25th, Boxer Capital Management, Llc sold 633,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $6.87, for a total value of $4,348,710.00.
• On Monday, October 21st, Boxer Capital Management, Llc sold 625,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.05, for a total transaction of $4,406,250.00.

Tango Therapeutics Stock Performance

NASDAQ TNGX opened at $2.83 on Friday. Tango Therapeutics, Inc. has a twelve month low of $2.77 and a twelve month high of $13.01. The stock has a market cap of $303.22 million, a PE ratio of -2.40 and a beta of 0.88. The firm has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $8.31.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.07. The company had revenue of $11.61 million for the quarter, compared to analyst estimates of $8.04 million. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. Research analysts forecast that Tango Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Tango Therapeutics by 32.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after acquiring an additional 7,128 shares during the period. SG Americas Securities LLC raised its position in Tango Therapeutics by 16.0% in the first quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after purchasing an additional 4,203 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Tango Therapeutics during the first quarter worth about $272,000. Vanguard Group Inc. boosted its holdings in Tango Therapeutics by 3.4% during the first quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock valued at $24,462,000 after purchasing an additional 101,673 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Tango Therapeutics by 12.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock valued at $102,000 after purchasing an additional 1,426 shares during the period. Institutional investors and hedge funds own 78.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TNGX shares. Wedbush raised their price target on shares of Tango Therapeutics from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Guggenheim reduced their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, October 28th. Finally, Jefferies Financial Group assumed coverage on shares of Tango Therapeutics in a report on Wednesday, July 17th. They set a “buy” rating and a $19.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $14.29.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.